AstraZeneca

Key TakeawaysDatopotamab deruxtecan addresses a critical gap in treatment options for EGFR-mutated NSCLC patients. Early trial results indicate a substantial improvement in response...

Key Takeaways • Tailored patient care is emphasized to meet individual health needs. • Reporting of adverse events is mandated to ensure ongoing safety monitoring. • Commissioners...

Key TakeawaysNovartis ranks first, with GSK following closely, yet overall progress in access to essential medicines remains stagnant. Only 43% of clinical trials...

Key TakeawaysAstraZeneca showcases infectious disease advancements with new data on RSV, hMPV, and COVID-19. Novel vaccine candidates IVX-A12 and AZD5148 show promise in...

Key TakeawaysAstraZeneca’s Wainzua (eplontersen) recommended for EU approval for treating hereditary transthyretin-mediated amyloidosis (ATTRv-PN) with polyneuropathy. NEURO-TTRansform trial shows Wainzua improves neuropathy impairment...

Key TakeawaysFasenra (benralizumab) gains EU approval for treating eosinophilic granulomatosis with polyangiitis (EGPA), providing a new option for patients. The approval is based...

Key TakeawaysENHERTU (trastuzumab deruxtecan) has received conditional approval in China, providing the first targeted therapy for HER2 mutant metastatic non-small cell lung cancer...

Key TakeawaysAstraZeneca partners with CSPC to develop YS2302018, a novel Lipoprotein (a) disruptor for cardiovascular disease. YS2302018 aims to address elevated Lp(a), a...

Key TakeawaysAirsupra significantly reduced the risk of severe exacerbations in mild asthma compared to albuterol alone. The BATURA trial was stopped early due...

Key TakeawaysTagrisso has been approved by the FDA for treating adult patients with unresectable Stage III EGFR-mutated non-small cell lung cancer following chemoradiation...

Key TakeawaysThe FDA has granted Priority Review to Enhertu for the treatment of HER2-low and HER2-ultralow metastatic breast cancer, based on positive results...

Key TakeawaysThe FDA has granted Priority Review for AstraZeneca's Calquence, a promising new treatment for untreated mantle cell lymphoma, based on data showing...

Key TakeawaysEnhertu received Priority Review for HER2-low and HER2-ultralow metastatic breast cancer after endocrine therapy. Phase 3 trial showed Enhertu improved progression-free survival...

Key TakeawaysCalquence granted Priority Review by the FDA for first-line treatment of mantle cell lymphoma (MCL). Phase 3 trial data showed a 27%...

Key TakeawaysThe strategic collaboration between Moffitt Cancer Center and AstraZeneca aims to accelerate the development of innovative oncology cell therapies, including CAR T...